Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"HCW Files for $50M IPO to Trial Fusion Protein in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics\u2019 Novel Bifunctional Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference, May 23-25, 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Patent Issued to HCW Biologics for Foundational Platform Technology","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Prime Capital Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by HCW Biologics

    Menu

    HCW Biologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HCW Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

              Details:

              The net proceeds will fund multiple Phase 2 trials in cancer, to evaluate HCW9218, the Company’s injectable, bifunctional fusion protein for reduction of senescence; and a Phase 1b study in an autoimmune disease to evaluate HCW9302, an injectable, IL-2-based fusion compound.

              Lead Product(s): HCW9218

              Therapeutic Area: Oncology Product Name: HCW9218

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Prime Capital Ventures

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing April 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HCW Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

              Details:

              Preclinical studies in mouse models have demonstrated the ability of HCW9302 to activate Treg cells and reduce inflammation-related disease pathologies, supporting the potential of HCW9302 to treat a wide variety of autoimmune and proinflammatory diseases.

              Lead Product(s): HCW9302

              Therapeutic Area: Immunology Product Name: HCW9302

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HCW Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference, May 23-25, 2022

              Details:

              HCW9218 is novel bi-functional fusion protein complex administered by injection. It is comprised of a soluble fusion of two human TGFβRII domains, human tissue factor, and human IL-15, and second soluble fusion of two human TGFβRII domains and a sushi domain of human IL-15Rα.

              Lead Product(s): HCW9218

              Therapeutic Area: Oncology Product Name: HCW9218

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HCW Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HCW Biologics CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022

              Details:

              Preclinical data from in vivo animal studies demonstrated ability of HCW9218, to both enhance anti-tumor efficacy of chemotherapy drugs and diminish their harmful side effects by reducing therapy-induced senescence and eliminating TGF-β and its immunosuppressive effects.

              Lead Product(s): HCW9218

              Therapeutic Area: Oncology Product Name: HCW9218

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HCW Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifun...

              Details:

              UM cleared to proceed with clinical trial to evaluate HCW9218, activates IL-15R signaling in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers.

              Lead Product(s): HCW9218

              Therapeutic Area: Oncology Product Name: HCW9218

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: University of Minnesota

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HCW Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer

              Details:

              HCW9218 is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.

              Lead Product(s): HCW9218

              Therapeutic Area: Oncology Product Name: HCW9218

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HCW Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218

              Details:

              HCW9218 is a heterodimeric, bifunctional fusion protein complex comprising extracellular domains of the human TGF-β receptor II, as TGF-β trap for TGF-β neutralization, and a human interleukin (IL)-15/IL-15 receptor α complex for immune-cell stimulation.

              Lead Product(s): HCW9218

              Therapeutic Area: Oncology Product Name: HCW9218

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HCW Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HCW Files for $50M IPO to Trial Fusion Protein in Solid Tumors

              Details:

              HCW9218, a bifunctional fusion protein, displayed strong anti-tumor activity mediated by NK cells and CD8+ T cells, and increased infiltration of NK cells and CD8+ T cells into tumors.

              Lead Product(s): HCW9218

              Therapeutic Area: Oncology Product Name: HCW9218

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $50.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering May 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY